Archive | June, 2010

Auxilium (AUXL) Holding Up After Barron’s “Not-So-Great Math”

Auxilium (AUXL) shares held up today ($24.85 up 0.65%) after a June 28 article questioned the valuation of the stock. Revenues for the last quarter were $45.5M primarily from its Testim testosterone gel, with a loss of $8.6M.Analysts have high expectations for a recently approved drug Xiaflex for treatment of Dupuytren’s disease and  reduce surgery […]

Continue Reading 0

Oncology Pipeline Update

Here is an update on Oncology Pipelines courtesy of Linda Pullan (lpullan@msn.com), a consultant who follows the sector. www.PullanConsulting.com Pfizer (PFE), Roche (RHHBY) and Novartis (NVS) are predicted to launch the most drugs. Some Pharma Companies Need to In-License in Oncology Now by Linda Pullan___________________________________________ Pharma and Biotech companies that can’t replace or outpace current […]

Continue Reading 0

Supergen(SUPG) in a Rally Mode at $2.43;Reiterate Buy

Supergen (SUPG) has been moving up steadily over the past few days since its low in the $2.10+ range this week.SUPG is in the Rayno Life Science Portfolio. The April 15,2010 high was $3.72.The balance sheet is strong with over $100M in cash,Shareholder Equity of $106M and no debt. Market Cap is $147M. Revenue for […]

Continue Reading 0

Post-ASCO Doldrums

Market Risk is Up-Speculation Is Off-Look for Value The news out of ASCO was not that new and exciting but it is even harder to find anything positive to write about three weeks later. Investors are “hiding out”. The overall market has cooled down from the recent rally and macro news has not been good: […]

Continue Reading 0

Multinational Drug Stocks and the Euro ETF(FXE)

Large Cap drug stocks have rallied over the past week as the market was up overall but also because the Euro was up 3% over the past 4 days. Is the correlation there? Well look at these charts tracking drug multinationals and the Euro through the ETF FXE. Pfizer (PFE) and Abbott (ABT) track well […]

Continue Reading 0

Genomics Boom Boosts Sales of Research Tools

Genomics and Medicine: transformative therapies are coming but diagnostic breakthroughs will lead the way Ten years after the start of the Human Genome Project  we have learned a lot about the links between genetics and disease but few direct cures have emerged. The biotech Company Human Genome Sciences(HGSI), an early player in genome discovery has […]

Continue Reading 0

Rayno Life Science Portfolio Update: Finally a Rally Day

Any momentum in biotech stocks from ASCO have been eclipsed by bearish, volatile trends overall.  There were some nice moves up today with the Rayno Life Science Portfolio was up 2.67% and all bio ETF’s did well: FBT up 3%,XBI up 3.48%, and IBB up 3.11%. Among the big movers in the Rayno Portfolio were: […]

Continue Reading 0

ASCO: Little Help for Biotech Stocks

Two Big Winners in Bristol Myers Squibb and Celgene The American Society of Oncology Meeting is normally good times for biotech as scientific and clinical developments propel stocks. This year the personalized medicine theme with potential breakthroughs in  targeted therapy for cancer is expected show excellent clinical results. In advance of ASCO Bristol Myers(BMY) presented […]

Continue Reading 0

Cubist (CBST) Pharmaceuticals Up 3% on Heavy Volume

In a nasty market where many indices are down 2.5% or more Cubist bucks the trend up 3% apparently on a Cowen and Co. upgrade from Neutral to Outperform.As of midday trading with a Volume of 2.8M shares the stock is at $22.25 up from $21.5 yesterday. The stock is up this year reaching a […]

Continue Reading 0